The study1, which was conducted in collaboration with Plymouth University, sought to find out what influences owners to buy a flat-faced breed, and once this decision has been made, how they go about acquiring a puppy. The study surveyed owners of the top 10 most popular Kennel Club registered breeds in the UK, to compare how influences upon breed choice and purchasing processes differed between owners of flat-faced breeds and popular longer-faced breeds.
Appearance was found to be the number one reason owners purchase flat-faced breeds, attracted by their large, round, wide-set eyes, and flat rounded faces. However, such characteristics are linked with lifelong respiratory, eye and skin problems, and a reduced lifespan compared with longer-faced breeds.
Key influencing factors associated with the choice of a brachycephalic breed included:
When it came to buying a flat-faced dog, owners were:
Dr Rowena Packer, lead author of the study and Research Fellow at RVC, said: "With their small size and baby-like features, some people cannot resist the looks of a brachycephalic dog. With growing evidence that these breeds are faced with a range of chronic and severe health conditions directly linked with their appearance, it is of huge concern that many people drawn to these breeds prioritise a dog’s looks over their long-term health and wellbeing.
"Potential puppy buyers attracted to the appearance of these breeds should seriously consider whether they are emotionally and financially prepared to take on a breed with high risks of health complications, and consider whether alternative, lower-risk breeds would better fit their lifestyle."
Co-author of the study and Associate Professor of Animal Welfare at Plymouth University, Dr Mark Farnworth, said: "Owners must be aware that as puppy-buyers, they are consumers, and their choices affect not only the health of the puppy they purchase, but also the health of the breed more widely. If owners do not follow recommended processes when purchasing a puppy, for example those set out in BVA AWF & RSPCA ‘Puppy Contract’, unscrupulous breeders will be kept in business, and continue to profit from the breeding and sale of unhealthy dogs. Without consumer awareness, breed health improvements are not possible and the overall health of these breeds will likely decline."
Paula Boyden, Dogs Trust Veterinary Director said: "The increased popularity of breeds such as Pugs, French Bulldogs and English Bulldogs is a huge welfare concern, particularly as this research indicates that the health of the breed was not a major consideration for potential puppy buyers. Many people mistakenly believe that the breathing sounds these breeds often make are endearing traits, rather than an indication of respiratory problems associated with their conformation. Dogs Trust urges anyone thinking of getting a puppy to look beyond the appearance of a breed, understand the impact on health, research the seller and buy responsibly."
Researchers say that the French Bulldog is set to become the most registered dog in 2017, overtaking the Labrador Retrievers’ 27-year reign at the top. The study therefore makes a number of recommendations, including:
Reference
Photo: Wikipedia CC BY-SA 3.0 Credit: Cristorresfer
The research, carried out by PhD student, Dr Sarah Finnegan and a multidisciplinary team of neurologists, behaviourists and biologists, found that 65% of owners reported pre-seizure changes in their dog, most commonly clinginess, excessive energy, and unsettled sleep. These signs varied between dogs, with other common changes including clumsiness, excessive panting, becoming withdrawn or quiet, and lacking energy.
43% of owners also reported seizure triggers, which commonly involved stress, food and excitement. A wide range of other triggers were reported by owners including loud noises, fireworks, storms, household products (cleaning products and air freshener), and preventative healthcare including flea and worming products and vaccinations.
60% of owners believed they were able to predict an upcoming seizure in their dog by using a combination of pre-seizure changes and recognising triggers. Nearly half of these owners were able to do so 30 minutes or more before the seizure commenced.
Dr Rowena Packer, BBSRC Research Fellow and research lead in canine epilepsy at the RVC, said: "It was fascinating to discover how in-tune many owners of dogs with epilepsy are with subtle changes in their dog’s behaviour before seizures. Many of our findings echo what is seen in human epilepsy patients and add evidence to support the presence of prodromal pre-seizure periods in dogs as well as people.
"Collecting further objective data to confirm these findings and explore ways to proactively utilise this period for seizure management are of priority for future research.
“This study also highlights how crucial it is that owners of dogs with epilepsy keep good records, not just of their dog’s seizures, but also of changes in behaviour and exposure to potential triggers, to gain a better picture of patterns in their dog’s seizure activity. The RVC Pet Epilepsy Tracker app allows owners to keep records, that can also be shared electronically with their vet and with RVC for further research.”
The new directive, set out in a consensus statement led by neurologist Dr Marios Charalambous, Neurology Consultant at Blaise Veterinary Referral Hospital, champions a stage-based and prompt approach which targets the abnormal impediments responsible for sustaining seizure activity and establishing refractory stages.
Marios said: "This consensus statement is the culmination of extensive research and experience in managing complex neurological emergencies.
"By formulating clear and universally applicable guidelines for all vets, it presents both a novel perspective in terms of how seizures should be treated, and a huge step forward in this specific field."
Marios was joined by a panel of clinicians including Karen Muñana, Ned E. Patterson, Simon R. Platt, and Holger A. Volk, who have jointly made these recommendations based on prevailing evidence in peer-reviewed literature, as well as their own extensive clinical experience.
It was then validated by the ACVIM Board-Certified Specialists before being distributed globally by ACVIM to form official guidelines for vets across the world.
Marios will be presenting and discussing his findings at the BSAVA Congress 2024 in Manchester this weekend as part of the neurology agenda on Saturday 23 March 2024.
Dan Lewis, National ECC Lead at IVC Evidensia, said: “Being presented with an actively seizing animal can be incredibly stressful for owners and clinicians and has potentially dire consequences.
"Decision-making under such circumstances is often very difficult, even for the most knowledgeable teams, and access to these straightforward treatment guidelines will make a massive difference to how these cases progress.”
https://onlinelibrary.wiley.com/doi/10.1111/jvim.16928.
Merial has announced the launch of NexGard Spectra, a broad spectrum oral parasiticide for dogs.
NexGard Spectra contains afoxolaner, which kills fleas and ticks on dogs, and milbemycin oxime, which is effective against roundworms, hookworms and whipworms.
The new product is delivered in a beef flavoured chew to help compliance.
NexGard Spectrum is available in five different weight ranges to suit puppies and dogs of all sizes.
Dr Crawford sent the email to his client, Mrs X, on 15 July 2014, the day on which Mrs X’s horse was due for insemination using horse semen supplied from a horse in Germany. However, the semen had arrived without the Intra Trade Certificate, a requirement for intra-EU inseminations, and so Dr Crawford proceeded to contact the Department for the Environment, Food and Rural Affairs (Defra) for alternative authorisation.
Just after 4:30pm on that day, Mrs X received a text from Dr Crawford advising her that he had received authorisation from the AHVLA, and would forward to Mrs X the AHVLA authorisation email. It later transpired that that the email had in fact been fabricated by Dr Crawford using an email that he had previously received from the AHVLA regarding another matter.
Dr Crawford faced the following charges:
Fabricating an e-mail purporting to be from the veterinary officer at the AVHLA, authorising use of semen from a horse for insemination, when in fact he had not received such authorisation.
Dishonesty in relation to the e-mail described above.
His conduct gave rise to spread of infectious disease which had the potential to affect equine animal health and welfare in the region.
Dr Crawford admitted the first two charges, but denied that his actions had given rise to the risk of disease.
The Committee found the first two charges proved, and moved on to determine the facts of the third charge. They took into account that Dr Crawford had received verbal confirmation that the semen was safe, and that the health papers had been stamped accordingly. He had not, however, seen a copy of this certificate and so there was no guarantee that the semen was safe to use at the time he sent the fabricated email. On consideration of the facts, the Committee found this charge proved, as Mrs X’s mare could have been infected and subsequently could have adversely affected equine animal health and welfare in the region.
They also found that his entire course of action had fallen far short of what is expected of a veterinary surgeon, and that it amounted to disgraceful conduct in a professional respect.
When determining sanction, the Committee took into account a number of aggravating factors, namely the risk of injury to animals, an element of pre-meditation, a disregard for the role of the AHVLA, impersonating a fellow veterinary surgeon, and intending to deceive a veterinary surgeon as well as a member of the public.
It did also, however, take into account the mitigating factors – that there was no injury to the animal, and that it was a single isolated incident from which Dr Crawford did not stand to make any financial gain.
The Committee therefore decided to order the Registrar to suspend Dr Crawford’s registration for 12 months.
Ian Green, chairing the Committee and speaking on its behalf, said: "The Committee did consider whether to remove Dr Crawford from the Register. However, in light of the significant mitigation in this case, the fact that this was an isolated incident in an otherwise unblemished career, together with his acceptance from the outset that he had been dishonest and his assurance that he would never behave in this way again, the Committee decided that in all the circumstances to remove him from the Register would be disproportionate."
Dr Crawford can lodge an appeal with the Privy Council within 28 days of being notified of the Disciplinary Committee's decision.
Zoetis, maker of Zylexis, is highlighting a new review published in Veterinary Immunology and Immunopathology, which has concluded that immune-modulators may provide a valuable contribution to the reduction of some equine respiratory diseases
The study reviewed the immune-modulators Parapoxvirus ovis and Propionbacterium acnes for the prevention of respiratory disease and other infections in the horse.
Parapoxvirus ovis (iPPVO) and Propionibacterium acnes (P.acnes) are currently used in equine medicine as immune-modulators for prophylactic treatment or adjunct to conventional therapy in order to improve immune defences, to prevent or treat infectious diseases. Their mode of action relies on a non-antigen-specific interaction with the innate and/or adaptive immune responses. iPPVO stimulates and regulates cytokine secretion by a number of leucocytes, while P. acnes acts primarily through activation of macrophages.
The review, conducted by Romain Paillot of the Animal Health Trust, Centre for Preventive Medicine, Newmarket, examined current scientific literature and reports on the use of immune-modulators in horses, particularly for the prevention or treatment of equine respiratory disease.
Stress factors such as weaning, transport and co-mingling predispose horses to infection and increase susceptibility to respiratory pathogens such as Streptococcus zoopidemicus and EHV-1/4. In the past 15 years iPPVO has been tested against several equine infectious respiratory diseases.
The review examined the results of studies on the beneficial use of iPPVO to limit the severity of respiratory infectious diseases in young horses, one of which evaluated the use of iPPVO for protection in yearlings exposed by contact challenge to EHV-1 or EHV-42,3,4. Yearlings treated with iPPVO were co-mingled with horses experimentally infected with EHV-1 and the trial was repeated with horses infected with EHV-4. Horses treated with iPPVO showed a 40% reduction in disease severity in the EHV-1 study and a 61% reduction in the EHV-4 study.
Further studies showed significantly increased frequency of recovery in horses with clinical signs of respiratory disease that had been treated with P. acnes. The decrease in disease severity was also significantly improved in the treated groups5,6.
Romain Palliot concluded: "Non-specific immune-modulators such as iPPVO or P. acnes may not provide protection against direct infection or transmission of respiratory pathogens but they seem to contribute to the reduction of the disease severity, subsequently reducing the frequency of complications and improving the rate of recovery."
References
Mr Shillabeer faced five charges which largely related to his alleged prescription of contra-indicated NSAIDs and corticosteroids.
He was also charged with prescribing frusemide to a pregnant dog when there was no evidence of a benefit of so doing.
He was also charged with performing inadequate spay surgery.
Mr Shillabeer did not admit to any of the charges, engaged with the College and responded to all requests for information, as well as being present in-person at the hearing.
He made an application to the Committee to dispose of the matter by way of adjournment, subject to the Committee accepting his written undertaking to remove his name from the Register and never to apply to be restored to the Register.
In support of his application, Mr Shillabeer’s legal counsel referred to his client’s witness statement, which set out that he had previously attempted to sell his practice but had been unsuccessful and that he had since closed it.
His legal counsel also asked the Committee to consider the fact that Mr Shillabeer is almost 85 years old and has had an unblemished 60-year career, has had no previous disciplinary findings against him, had put his practice up for sale and made efforts to guide his previous clients to ensure continuity of care elsewhere, and that he deeply regrets anything he has done, which has failed to protect the welfare of animals, or has caused concern or upset to his clients and fellow members of the profession.
Mr Shillabeer's counsel also asked the Committee to take into consideration that his undertakings would have the effect of protecting the welfare of animals and uphold the reputation of the profession as Mr Shillabeer is no longer in practice.
He stated it would be not proportionate, or in the public interest, for there to be a lengthy contested hearing resulting in substantial costs for both the RCVS and Mr Shillabeer.
The College’s legal representative stated that the RCVS did not oppose the application, and that it took a neutral stance.
She highlighted that Mr Shillabeer’s removal from the Register, together with his undertaking never to apply for restoration, would go far beyond anything the Committee could direct by way of sanction after a full enquiry, that Mr Shillabeer retired from practice on 23 July 2024 and does not intend to return, that a full enquiry would take a significant amount of time and expense, that the complainant supports the case being dealt with in the manner proposed by Mr Shillabeer, and that there are no previous findings against Mr Shillabeer.
Paul Morris, chairing the Committee and speaking on its behalf, said: “Taking into account the undertaking never to practice again, in conjunction with all of the circumstances and context set out, the Committee considered that by allowing the application, such an outcome would be sufficient to uphold the public interest, confidence in the profession and the RCVS as regulator, and protect the welfare of animals.
“As a result of all the factors set out, the Committee decided that this is not a case in which the public interest or the welfare of animals demands that there be a full hearing.
“Taking into account proportionality and weighing in the balance all the circumstances of the case, the interests of justice, the public interest, the need to uphold proper standards of conduct and performance, and the need to protect the welfare of animals, the Committee decided to grant the respondent’s application.”
Mr Shillabeer was removed from the Register with immediate effect.
https://www.rcvs.org.uk/concerns/disciplinary-hearings/
Forum Animal Health has launched the new Agger's Cattle Pump Lite for oral fluid therapy in cows.
The pump allows one man to deliver 20 litres of fluid into the rumen in just 2 minutes. According to the company, it offers even more benefits: it is robust and lighter to carry, more convenient with its new quick-release connector and more economic: less than half price than the previous version.
Forum Animal Health says the Agger's Cattle Pump is very successful for oral administration of fluids, electrolytes and specific nutrients directly into the rumen. Designed for vets to make oral fluid therapy quick and easy to administer without assistance, many vets have found the Agger's Cattle Pump so useful for routine fluid therapy that they have trained their clients to use it, given them protocols for fluid therapy and supplied them with their own pumps. On-farm training support is available for your clients.
The New Agger's Cattle Pump Lite is available now. For more information, please contact Forum Animal Health on 01737 781416 or animal.health@forumgroup.co.uk.
Ubroseal is licenced for the prevention of new intramammary infections throughout the dry period. In cows considered likely to be free of sub-clinical mastitis, the product can be used on its own in dry cow management and mastitis control.
Boehringer's veterinary adviser, Kath Aplin said: "Ubroseal features a flexi-cap to reduce the risk of teat canal damage and its unique longer plunger makes application more ergonomic and significantly easier for the farmer."
The launch coincides with the publication of a statement by an expert group convened by Boehringer1 which recommends the administration of an internal teat sealant at drying off to all cows on all farms.
For more information, contact: vetenquiries@boehringer-ingelheim.com.
Danny Chambers MRCVS had a disappointing night after seeing the Liberal Democrat share of the vote in North Cornwall decrease by 5.8%, leaving him trailing 14,752 votes behind the Conservative candidate Scott Mann who scored 30,671.
Meanwhile Ian Fleming MRCVS, who stood as an independent candidate for the Halesowen and Rowley Regis constituency, got 190 votes. The winning Conservative candidate, James Morris, gained 25,607 votes.
Many people will no doubt feel that the overall Conservative majority of 80 seats is a disastrous result; people who simply cannot bear Boris and fear what he'll do with a majority; people who saw a land of milk and honey and free broadband and publicly-owned railways that run on time and an A&E waiting time of less than 30 seconds and guillotines for the rich, only to have their hopes dashed. They must be gutted.
Equally it can be argued that this is the best possible result for the country. A decisive vote. Now, finally, we can all move on from 3 years of interminable debate about whether we're staying or going or having another referendum or cancelling the whole thing and going down the pub instead. Now the government can concentrate on implementing brexit. Perhaps the country can at last unite around that purpose.
Boris may not prove the disaster that some people think. He's not hard right. Quite the reverse. And having won all those safe Labour seats, he'll have to deliver for them. He has a good sense of humour ("Let's get breakfast done."), but that does not make him a fool or a charlatan. On the contrary, wit requires brainpower. And as for the accusations of being a liar, perhaps people will come to understand that flowery use of language does not itself make someone dishonest. Perhaps people will learn to stop interpreting his words so literally.
Time will tell, but there is cause for optimism this morning. Whichever side of the fence you sit, we must all be glad of one thing ... no more arguing about whether or not we're leaving.
The committee considered 5 separate charges against Dr Radev, relating to his treatment of a Yorkshire Terrier and Shih Tzu cross called Pickles at a Vets4Pets veterinary practice in Oxford between 5 October 2015 and 1 November 2015. The charges related to Dr Radev failing to provide adequate and/or appropriate care to the animal and failure to keep detailed clinical records.
After hearing the evidence from Dr Radev and the complainant, the College submitted that it wished to withdraw charges 1(i) and 1(ii) on the basis of insufficient evidence. In addition, Dr Radev had already admitted charges: 1(iii)(b), 1(iv)(d), 1(v), 4(i)(a) and 4(ii)(a) but denied the remaining charges. Of these remaining charges the Committee found charges 1(iv)(a), 2(i), 2(iv), 3(i) and 3(ii) proven with the rest not being proven.
The charges admitted or found proven were that Dr Radev:
(1) On 5 October 2015, failed to provide adequate and/or appropriate care and/or treatment to Pickles, more particularly in that he:
(iii) Failed to offer and/or undertake adequate investigations into Pickles’ condition, more particularly in that he failed to offer and/or undertake:
(b) urine tests;
(iv) Failed to put in place and/or document an adequate management plan for Pickles, more particularly in relation to:
(a) adequate direction and/or advice regarding a review of Pickles’ condition within a clearly defined number of days;
(d) collection of urine at home for analysis on review at the practice;
(v) Having noted that he suspected renal disease, prescribed meloxicam when the same was contraindicated for dogs with renal disease;
(2) On 28 October 2015, failed to provide adequate and/or appropriate care and/or treatment to Pickles, more particularly in that he:
(i) Failed to take and/or record an adequate history from Mrs Pancott in relation to Pickles’ condition and/or clinical signs since 5 October 2015;
(iv) Failed to provide adequate direction and/or advice regarding a date for a review of Pickles’ condition within a clearly defined number of days;
(3) On 30 October 2015, having been informed that Mrs Pancott had telephoned the practice with concerns about Pickles, including blood in the faeces;
(i) Failed to note the matter in Pickles’ medical records;
(ii) Failed to take sufficient steps to obtain more information from Mrs Pancott or to ensure that Mrs Pancott was advised to seek veterinary attention for Pickles in relation to her concerns;
(4) On 1 November 2015, failed to provide adequate and/or appropriate care and/or treatment to Pickles, more particularly in that he:
(i) Failed to interpret the blood tests adequately and/or take appropriate and adequate action in relation to the results of those blood tests, more particularly with regards to:
(a) blood glucose;
(ii) Failed to offer and/or undertake adequate investigations into Pickles’ condition, more particularly in that he failed to:
(a) offer and/or undertake urine tests.
In considering these charges the Disciplinary Committee found that only charge 4(ii)(a) – namely the failure to correctly interpret and act upon the results of a blood glucose test – amounted to serious professional conduct with the rest not passing the threshold of disgraceful conduct in a professional respect. The Committee did not consider that in addition the cumulative effect of all the proven charges taken together amounted to serious professional misconduct.
In relation to the cumulative effect of all the proven charges Professor Alistair Barr, chairing the Committee and speaking on its behalf, said: "The Committee noted that Dr Radev had made errors in relation to one patient but on four separate occasions. These were, for the most part, individual failures at the lower end of the scale of seriousness. Taking into account all of the failings, the Committee in its judgement did not consider that the nature and number of errors and the period of time over which they took place justified a cumulative finding of disgraceful conduct."
In considering the sanction for Dr Radev the Committee took into account a number of mitigating circumstances including the fact that Dr Radev had undertaken suitable training and development in the areas in which he made mistakes, had demonstrated good insight into his conduct and had made some open and frank admissions early on in proceedings. It also considered that the one charge that was found to be serious professional misconduct was a single, isolated mistake linked to Dr Radev’s inexperience.
Professor Barr said: "The Committee considered that taking ‘no further action’ was appropriate and proportionate having considered the history of the case, the Committee’s overall findings and the good reports of Dr Radev’s performance in the two years since the matter which had led to the finding of disgraceful conduct in a professional respect."
The decision to take no further action was also influenced by the length of time it had taken the charges to be heard by the Committee, the positive character references about Dr Radev from professional colleagues and the fact he was unlikely to repeat such conduct in the future.
Suvaxyn PRRS MLV offers the earliest piglet vaccination from the first day of age, securing immunity before the risk period which lasts until the end of the fattening. Pig protection is established 28 days after vaccination, and lasts for 26 weeks after vaccination in fattening pigs, and 16 weeks after vaccination in gilts and sows. Zoetis says the vaccine reduces viremia and nasal shedding of the virus.
Monica Balasch, Associate Director, Global Biologicals Development at Zoetis said: "In Europe, Porcine Reproductive and Respiratory Syndrome is known for severe impacts on reproduction including lowering birth rates, increasing abortion, stillbirth, mummified, as well as weak live-born piglets, and death.
"In clinical studies conducted with Suvaxyn PRRS MLV, we found excellent results vaccinating pigs from the first day of age. It is safe to be used as the earliest protection in piglets, and to protect the whole herd against PRRS, as it is also safe for use in gilts and sows.
"The new vaccine represents a flexible alternative to allow for new customized PRRS control programs developed by veterinarians for producers."
Alvaro Aldaz, Director, Commercial Development and Innovation, Swine, at Zoetis said: "We are excited to bring this innovative vaccine to Europe. Suvaxyn PRRS MLV has been developed using a very innovative vaccine technology which brings swine veterinarians a new advanced PRRS control tool.
"As well reducing viremia, nasal shedding and lung lesions in fattening pigs, the vaccine has been proven to overcome maternal immunity, which increases the efficacy of the vaccine when given to piglets during the first days of life. Additionally, it allows veterinarians for use PRRS mass vaccination within the claim; mass vaccination has become more and more popular in several European countries."
Suvaxyn PRRS MLV is a veterinary vaccine that contains a European PRRS virus strain (Genotype 1) that has been grown and attenuated in a uniquely modified cell line developed by Zoetis.
Jay Calvert, Research Director, VMRD Global Biologicals Research at Zoetis said: "Suvaxyn PRRS MLV is safe based on true loss of virulence, and not based on a temporary reduction in ability to replicate in macrophage cells in the lung of the pig."
Zoetis says the efficacy of Suvaxyn PRRS MLV is supported by a comprehensive program of clinical studies reviewed by the European Medicines Agency and included in the regulatory procedure approved by the European Commission in August 2017.
The European public assessment report is available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/veterinary/004276/WC500235212.pdf
The company says the most common side effects with Suvaxyn PRRS MLV (which may affect more than one in 10 pigs) are a short-lived increase in body temperature (0.5°C on average and up to 1.4°C individually) within four days of vaccination, and in sows local reactions in the form of swellings which resolve without treatment within five to 32 days.
Amy Scott MRCVS, Boehringer Ingehlheim’s performance horse portfolio manager, said: "Arti-Cell Forte is the first 'ready-to-use' stem cell-based product to be licensed in any veterinary species, and the only stem cell treatment to contain induced cells, representing a significant leap forward in both stem cell therapies and medicine as a whole.
"Arti-Cell Forte contains stem cells that have been chondrogenically induced and therefore primed to develop into the cartilage cell lineage. Studies have shown that chondrogenically induced stem cells demonstrate an enhanced clinical outcome compared to un-induced stem cells in the treatment of joint disease in horses¹."
"This makes Arti-Cell Forte a highly targeted and effective treatment for cartilage damage associated with degenerative joint disease."
Arti-Cell Forte is available direct from Boehringer Ingelheim to veterinary practitioners.
It needs to be stored at ultra-low temperatures to maintain its two year shelf life from manufacture, either frozen at -70 ⁰C to -90 ⁰C (dry ice, -80 ⁰C freezer) or -196 ⁰C (liquid nitrogen) until immediately prior to injecting.
The company is providing full training on storage and administration via face-to-face CPD at practice meetings or specific CPD events*.
For more information, contact your local territory manager or ring Boehringer's Technical Services Team on 01344 746957, or email vetenquiries@boehringer-ingelheim.com
RCVS President Neil Smith has issued a statement in response to the petition by Devon vet Jo Dyer which called for the removal of mandatory house visits from the Code of Professional Conduct and received just shy of 1300 signatures over the past 48 hours.
The statement reads:
"I am delighted to see that so many veterinary surgeons are taking seriously our call for views and evidence on all aspects of the provision of 24-hour emergency cover, including those who have signed up to veterinary surgeon Jo Dyer's petition calling for the removal of 'mandatory house visits' from the Code of Professional Conduct.
"However, I am concerned that the petition is working on a misunderstanding. Veterinary surgeons are not mandated to attend away from the practice just because an owner has requested a visit. It is a professional decision based on a range of factors.
"In fact, paragraph 3.13 of the Supporting Guidance to the Code of Professional Conduct states 'Clients may request attendance on a sick or injured animal away from the practice premises and, in some circumstances, it may be desirable to do so. On rare occasions, it may be necessary on clinical or welfare grounds. The decision to attend away from the practice is for the veterinary surgeon, having carefully balanced the needs of the animal against the safety implications of making the visit; a veterinary surgeon is not expected to risk 'life or limb', or that of anyone else, to provide the service.'
"I appreciate that recent disciplinary hearings, especially that of Mr Chikosi, have increased concerns in the profession that vets will be disciplined for not turning out to every single request for a home visit. This is not the case. In order for someone to be taken to a disciplinary hearing for refusing to attend away from the practice, first there needs to be a complaint, and second, the Preliminary Investigation Committee needs to be convinced that the veterinary surgeon could not justify their decision. Such cases are rare. In fact, last year, only 3% of the complaints we received were about 24-hour cover, and not all of those related to home visits.
"Having said this, the number of signatures received on Jo Dyer's petition, and the comments of the signatories, will be fed into the material reviewed by the Standards Committee, alongside formal responses to our call for evidence, and views gathered from animal-owner research. Clearly if so many veterinary surgeons believe that house visits are mandatory in all circumstances, the wording of our guidance needs to be reviewed, at the very least.
"It is likely that any recommendations for change in our 24/7 policy would go to the June meeting of Council, although this timetable is subject to change, depending on the nature of the report from the Standards Committee."
For the research, Miele commissioned independent market research firm Sapio to interview 1000 pet owners and 100 UK-based vet practices.
Veterinary practices have good reason to worry about complaints: the research showed that 89% of veterinary clients would be quick to tell others if they were dissatisfied with any aspect of the practice or care received. 63% said they would air their grievances on an online review site and 60% said they'd share their views on social media.
Those figures appear to be borne out by the fact that only 10% of vets said they had not seen any negative comments online about their practice.
Interviews with pet owners also found that the top five factors to affect a practice's reputation were: standard of care, a clean and hygienic environment, good customer service, the cost of treatment and waiting times, in that order.
64% of vets agreed that practice hygiene has become increasingly important with cleanliness of staff uniforms and waiting rooms among the first things that customers notice.
The suitably spruce Sam Bailey (pictured right), Sales & Marketing Director for the Professional division of Miele said: "Vet practices are increasingly coming under the same online scrutiny as hotels and restaurants and are being judged on everything from customer service through to staff appearance and waiting times.
"As our research results show, vets are already concerned about their reputations and it’s not just customer service and care outcomes that matter to pet owners, they also have high expectations when it comes to the practice environment too and are looking at cleanliness, hygiene and staff appearance.
"Through our network of approved partners we are working with more and more vet practices throughout the UK to ensure their on premise laundries not only meet WRAS regulations but also support their standards on hygiene, infection control and cleanliness."
Alphazium TT contains alphalactalbumin and magnesium, which, according to the company, targets the three main neurological pathways involved in the regulation of mood and emotional balance.
TVM says Alphazium TT is highly palatable, so it can be administered as a treat, making the process stress free for veterinary staff, pets and pet owners.
TVM UK’s product manager Will Peel said: "Behavioural problems are becoming increasingly common in cats and dogs and are these problems are likely to get worse with pet owners going back to work as lockdown measures lift, which could cause further stress and anxiety in pets.
"Alphazium TT can help owners address these problems whilst being highly palatable – therefore also reducing the stress of tablet administration all-round."
For more information and support materials, visit: https://www.tvm-uk.com/alphaziumtt/2520/ or contact your TVM UK Territory Manager.
The Daily Mail yesterday published a 'shocking exposé' which portrays the veterinary profession as one that 'puts pets through painful and unnecessary treatments to fleece their trusting owners'.
The story is based on an interview with ex-vet Matthew Watkinson to promote his new book: 'On The Destiny Of Species'.
In the interview, Mr Watkinson claims the veterinary profession is to blame for much of the animal suffering in the UK, and that 'money - not the welfare of the animal - is often at the forefront of the vet's mind'.
In the interview, Mr Watkinson
The RCVS issued a swift response, which you can read here.
Later in the day, Mr Watkinson appeared on Radio 5 Live opposite ex BVA President, Nicky Paull. The interview can be heard for the next 6 days on BBC iplayer here.
It is not yet clear the degree to which the Daily Mail might have sensationalised Mr Watkinson's interview. In his blog, he claims it did, but defiantly defends his main argument that the profession is fighting natural selection, and thereby harming animal welfare.
Seems to me that some aspects of Mr Watkinson's argument are perhaps worthy of debate, but they've been obscured by the glare of the critical headline, and the Daily Mail's predictable preoccupation with the sensational but unrepresentative. So I'm delighted to see that whilst writing this story, Mr Watkinson has joined us in the VetSurgeon forums to put forward his case.
Brave man.
The new devices are an evolution of the original v-gel device launched in 2012, which is widely used in veterinary anaesthesia and resuscitation.
Dr Muhammed Nasir, inventor of v-gel and President of Docsinnovent, said: "Our original product has proven to be extremely popular globally because it makes airway management easier; quicker; more comfortable for patients; and most importantly, safer for patients and staff.
"However, since launch our R&D team have been hard at work to make the devices even better. They are now slimmed down so that there is more room in the mouth for dentistry; they seal even better; and they are single-use, improving standards of hygiene"
Chris Geddes MRCVS, Docsinnovent’s Marketing Manager, added: "Our newly-launched website www.docsinnovent.com includes plentiful information on the new products including two hour-long CPD webinars from Dr Ivan Crotaz detailing how the new devices can be utilised for optimal airway management in anaesthetised patients.”
Information on where to buy the new products can be found at www.docsinnovent.com/distributors
According to the study1, which looked at Chihuahuas treated in first opinion practice, ownership in the UK has increased over five-fold in the past decade from 1.0% of all puppies born in 2005 to 5.4% in 2016.
However, the study also found the breed was particularly susceptible to a number of health issues, including: dental disease (13.5%), obesity (5.9%) and retained baby teeth (5.7%).
Compared with other dogs, Chihuahuas were also more prone to aggression (4.2%), slipping kneecap (4.0%) and retained testicles (3.9%).
Other findings included:
Dan O’Neill, senior lecturer at the RVC and author of the paper, said: "Chihuahuas are an old breed but the recent craze for them can cause some real welfare issues for this tiny dog. There is increasing evidence that unscrupulous breeders and dealers both inside and outside the UK are cashing in on this trend by making a lot of money but with little regard for the welfare of these puppies and breeding bitches."
Camilla Pegram, VetCompass epidemiologist at the RVC and co-author of the paper said: "Dental disease and retained baby teeth should be recognised as important health concerns for Chihuahuas, with preventative care for dental disease a key topic for discussion between vets and owners. In addition, many of the common or predisposed disorders, such as dental disease, retained baby teeth, sliding kneecap and retained testicle(s), often require surgical intervention. The Chihuahua’s small size increases its anaesthetic risk. Obesity has many detrimental effects, including increased anaesthetic risk, and aggression makes them challenging patients and pets, therefore nutrition, lifestyle and behaviour are also key areas for veterinary-owner discussions."
The full paper is open access: https://doi.org/10.1186/s12917-020-2258-1.
Reference:
Thiamacare contains 10 mg/ml thiamazole, which is double the concentration of Thyronorm, for a lower dose volume.
Animalcare highlights research which shows that 87.4% of owners prefer liquid medications for their cat1, and that cats find liquid presentations more palatable2.
James Beaumont from Animalcare said: "With the lowest dose volume available, we believe Thiamacare will make the medical management of this condition easier through improved cat acceptance and better owner compliance."
Thiamacare's dosing syringe is marked with a single scale in 1.25 mg increments to facilitate precise dosing in response to total T4 measurement values. The scale does not need converting when switching from other brands or formulations.
Animalcare has developed a range of supporting materials to encourage the use of Thiamacare as the preferred choice for feline hyperthyroid medical management. They include social posts and a post-prescription leaflet to help veterinary teams support owners, particularly through the stabilisation phase post-diagnosis.
A short webinar offering top tips for treating feline hyperthyroidism from feline Specialist Dr Caney will also be available later in October. These resources will all be available at www.the-pac.co.uk.
The plan is designed to help mimic the way cats eat in the wild and so provide them with both physical and mental stimulation. It also encourages cats to hunt, explore, climb and play – activities which boost cats’ positive behaviour and wellbeing.
Developed by feline behaviour specialist Dr. Sarah Ellis and Dr. Lizzie Rowe at International Cat Care, the plan is also designed to help to prevent overeating and promote a balance between energy intake and energy output, in order to avoid weight gain, as well as encouraging weight loss in overweight cats.
It is estimated that there are 10 million pet cats in the UK1 and the charity points to data which suggests that 39 – 52% of them are overweight or obese2,3, something which is a major health and welfare issue4-9, and can ultimately lead to early death10.
The charity says research shows that current feeding practices are contributing to this obesity epidemic, with a number of factors associated with a cat’s modern lifestyle leading to overeating. For example, most cats need little or no exertion to obtain their food, making it more likely that the calories they take in through eating will outweigh the calories they use up through exercise (leading to weight gain). Furthermore, the way we feed our cats generally does not match the lifestyle they were designed for, resulting in a lack of mental stimulation and reduced opportunity to express natural, instinctive hunting behaviours. This can lead to boredom, apathy, anxiety, frustration and stress in cats, resulting in reduced wellbeing and potentially the development of problem behaviours.
Sarah said: "By making a few simple changes to the way we feed our cats, we can help them to live longer, healthier and happier lives."
The plan recommends:
A detailed version of the feeding plan, along with the full report behind the development of the plan, can be found on International Cat Care’s website:
https://icatcare.org/advice/general-care/keeping-your-cat-healthy/feeding-your-cat-or-kitten
A short version of the feeding plan can also be found there.
Licensed for use from 6 weeks of age - and in pregnant and lactating bitches and queens - Evicto provides adulticidal, larvicidal and ovicidal flea protection, which can also help to control environmental flea infestations in areas where the pet has access. It also treats ear mites, biting lice, intestinal roundworms, sarcoptic mange in dogs, intestinal hookworms in cats and can be used to prevent heartworm disease with monthly administration.
Evicto is presented in packs of 4 pipettes which are transparent so owners can see that the full dose has been applied. The company also highlights that with Evicto pets can be bathed 2 hours after treatment without loss of efficacy.
Claire Lewis, Product Manager at Virbac said: "We are pleased to add Evicto to our award-winning range of parasite protection products.
"Evicto can also be used concurrently with Milpro, making it the perfect product partnership."
Evicto is available from the veterinary wholesalers now.
For information, speak to your Virbac Territory Manager.
Tablets are divisible into 15mg increments to enable accurate titration of dosing, come blister-packed to facilitate dispensing and are liver flavoured to help with compliance.
TVM says that in a first for a phenobarbital generic, Soliphen has proven bioequivalence to the market leading brand, which provides the reassurance of staying on-label when switching from the leading brand is necessary or desirable.
William Peel, Product Manager at TVM UK, said: "Phenobarbital is the only veterinary licensed drug for use in idiopathic and structural epilepsy, benefiting a large proportion of epileptic dogs with an improvement in seizure frequency. As a result, phenobarbital is a mainstay of treatment in epilepsy cases. With Soliphen, we have developed a cost-effective, easier and more accurate solution."
Soliphen is supported with a range of materials for use in practice, including owner booklets on epilepsy and in practice guidelines for the management of status epilepticus and chronic seizure control.
For more information, speak to your local TVM-UK Territory Manager, email: help@tvm-uk.com, visit: www.tvm-uk.com or call: 0800 0385868.
The clinic will offer referrals in orthopaedics, internal medicine, soft tissue surgery, neurology and advanced imaging from a team which includes Rory Bell, an RCVS and European Recognised Specialist in Internal Medicine, and Jonathan Bell, an EBVS and RCVS Specialist in Small Animal Surgery.
The practice says it has some of the most advanced equipment in Europe, including a Siemens 128 slice CT scanner and a Siemens 1.5T Aera MRI scanner. The clinic also has three environmentally-controlled theatres, with CT and MRI scanning capabilities.
Dr Stuart Cooke BVetMed CertSAS MRCVS, one of Swift Referrals founders said: “We’re delighted to launch Swift Referrals, and would like to thank everyone who helped us get here. We are proud to be able to say that we house some of the most advanced equipment in the continent, from the very best advanced imaging machines, to specialist treatment and aftercare rooms. We also have some of the most skilled veterinary experts operating in them, day in and day out. Our clinicians are leaders in their field of expertise, with years of experience and very advanced training."
For more information: www.swiftreferrals.co.uk/.
Veterinary surgeons have named their top new veterinary products of 2012 in a survey carried out by CM Research.
As part of the research, 343 vets working in UK practice were asked what they considered to be the best new product of 2012. Their answers were unprompted, and they were only allowed to mention one product or service. For this reason, some vets voted for products that were launched earlier than 2012. The full results were as follows:
Hill's y/dAn iodine restrictive hyperthyroid management food launched by Hill's Pet Nutrition in May 2012 won with an overwhelming 31% of the votes. www.hillspet.co.uk
Cardalis (CEVA Animal Health)Launched towards the end of 2012, CEVA's combined ACE inhibitor / spirolactone for heart failure in dogs scored a creditable 9.6% of mentions. www.ceva.co.uk
Seresto (Bayer Animal Health)Bayer's 8-month flea and tick collar came third with 6% of the votes. www.seresto.com.
Caninsulin Vetpen from MSDLaunched in July 2012, this new insulin delivery pen for Caninsulin is designed to improving dosing accuracy, consistency and ease of use. The user-friendly pen design is said to improve initial pet owner acceptance and on-going compliance.
Atopica Cat (Novartis Animal Health)Novartis launched Atopica Cat, an oral version of its treatment for chronic allergic dermatitis, at the start of 2012. www.itchfreepet.co.uk
Comfortis (Elanco)Launched in 2011, Comfortis is a novel oral flea adulticide for dogs which kills adult fleas rapidly for a month. www.comfortis.com
Nobivac Myxo RHD (MSD)The first vaccine to combine 12 months protection against both myxomatosis and rabbit haemorrhagic disease within a single inoculation. It is a non-adjuvanted vaccine which, according to MSD, delivers greater simplicity of protocol and enhanced disease protection.
Cimalgex (Vétoquinol)Launched towards the end of 2011, Vetoquinol's 2nd generation Cox-2 inhibitor is said by the company to be very well tolerated, have an excellent efficacy profile and be very easy to use, meaning that Cimalgex allows veterinary patients to benefit from pain relief in situations where clinicians would have been worried about the risks versus the benefits of prescribing a NSAID for pain management.
Activyl (MSD)MSD's novel flea spot-on is the first to work by bioactivation, only becoming an insecticide after being ingested by the flea, thus minimising owner's exposure to insecticides. Said to be effective against the other stages of the flea life cycle, too. www.activyl.co.uk
RevitaCAM (Abbott)RevitaCAM is the first and only veterinary NSAID (meloxicam) with oromucousal delivery. www.revitacam.co.uk.
Metacam for cats (Boehringer Ingelheim)Boehringer extended its Metacam 0.5 mg/ml Oral Suspension for Cats range with the launch of a 30ml bottle size in July. www.metacam.co.uk.
Zuprevo (MSD)MSD's antibiotic to combat bovine respiratory disease (BRD) was launched in the third quarter of 2011. www.zuprevo.com
V-Gel (Docsinnovent)V-gel was the first ever species-specific supraglottic airway device (pictured top right), currently available for cats and rabbits. Billed as the latest ground breaking technology for a safer anaesthesia, easier breathing and avoiding damage to the throat and trachea; a safer alternative to ET tubes. www.docsinnovent.com
Onsior (Novartis Animal Health)The tissue-selective oral and injectable Cox-2 inhibiting NSAID from Novartis was actually launched back in 2009.
Certifect (Merial)Merial's flea and tick spot-on for dogs was launched by Ray Mears in the UK in February 2012. www.certifect.co.uk
Calmex (VetPlus)Somewhat controversial when it made its first appearance in 2011, Calmex is a feed to help dogs and cats that may experience behavioural problems as a result of their environment or situations that may cause anxiety or fear. More info.
Comfortan (Dechra)The first licensed methadone for dogs was launched by Eurovet towards the end of 2011, before it was acquired by Dechra in May 2012. www.dechra.co.uk
Hill's Vet EssentialsHill's vet-exclusive petfood range is designed to meet essential dietary needs at every life stage. More info.
Trocoxil (Pfizer)Trocoxil, Pfizer's NSAID for canine osteoarthritis was remarkable for its once monthly dosage regime, when launched back in 2009.
VerafloxBayer launched its next generation fluoroquinolone antimicrobial for bacterial infections in cats and dogs at the end of 2011
YumoveYumove is a joint support supplement from Lintbells, containing glucosamine and chondroitin. More information.